Mendel vs xCures (2026)
Both turn unstructured records into structured clinical answers and they start from different failures. xCures starts from records that are not there, retrieving across local, state and national exchanges to assemble a longitudinal history before anything can be read, with peer reviewed publication behind the platform and a public trust page with control level detail. Mendel starts from records that are present and unreadable, pairing language models with symbolic reasoning over a clinical hypergraph specifically because generation alone produces confident errors in abstraction, and it can run inside the customer's own environment. For a community oncology network whose patients receive care in three health systems, retrieval is the binding constraint and xCures is aimed at it. For an academic centre with everything in one record and no capacity to read it, Mendel is the better fit and the safer residency answer.
- Peer reviewed validation of the platform and its decision support algorithm, plus structural oversight where treatment option outputs pass through a defined review step rather than reaching a clinician raw.
- Retrieval across local, state and national exchanges is the core competency, so it works for patients whose care has been delivered across institutions that never shared anything.
- A public trust page with a control level table and a named certification statement, alongside an unqualified business associate posture.
- Chart abstraction is the general capability rather than trial screening alone, so the same platform serves cohort building, observational research and prescreening.
- The architecture is deliberately hybrid, pairing language models with symbolic reasoning over a clinical hypergraph because generation alone produces confident abstraction errors.
- It can be hosted inside the customer's own environment, which is the strongest residency position among the trial vendors in this index.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Mendel and xCures are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Mendel | xCures |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Decision Support |
| Founded | 2016 | 2018 |
| Headquarters | San Jose, California, United States | Oakland, California |
| Website | mendel.ai | xcures.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Mendel its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against xCures, Mendel grades higher on FDA and Regulatory Status and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards xCures its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Mendel, xCures grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Mendel or xCures?
On the axes where the AI Health Index separates them, Mendel grades higher on FDA and Regulatory Status and Deployment Model and Data Residency, and xCures grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. xCures leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Mendel and xCures differ most?
The widest separation the AI Health Index records between Mendel and xCures is on HIPAA and BAA Posture, where Mendel grades C and xCures grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Mendel and xCures grade the same?
The AI Health Index grades Mendel and xCures the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two overlap in capability and differ in origin: one grew out of retrieving and structuring records that are physically scattered, the other out of reasoning over records that are present but unreadable, and a buyer should establish which problem dominates before comparing feature lists. Neither publishes pricing and neither publishes a false negative rate for eligibility screening, which is the number that matters most here. Mendel publishes no security attestation or trust centre. Both carry the documentation bias common to this category, where patients with sparse records are systematically less likely to surface.